REDWOOD CITY, California, June 9, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), is pleased to announce the appointment of Vince R. Anicetti as Senior Vice President, Global Quality. Mr. Anicetti joins Coherus with more than 30 years of experience in quality and regulatory affairs at preeminent biotech companies.
"Vince's breadth and depth of experience will be critical to delivering to patients high-quality biosimilars with robust consistency," said Denny Lanfear, President and CEO of Coherus. "We are thrilled to welcome Vince to the Coherus team as we advance global development and commercialization strategies across our portfolio."
"I am delighted to join the Coherus team and look forward to joining our effort to increase patient access to many important medicines," Mr. Anicetti stated. "Our management team is committed foremost to providing the highest quality products. It is a privilege to lead the development of our Quality Systems at Coherus."
Mr. Anicetti brings to Coherus an extensive background developing and leading Biopharmaceutical Quality organizations. Most recently he was the Executive Director of Quality for Boehringer-Ingelheim's California facility, responsible for Quality and on-site Regulatory Chemistry, Manufacturing, and Control. Mr. Anicetti also spent 30 years with Genentech and held senior leadership roles in Quality, Regulatory Affairs and Project Portfolio Management, including Vice President of Biologics Quality for Genentech and Roche Biologics manufacturing sites around the world. Mr. Anicetti is also an adjunct professor at the Keck Graduate Institute teaching classes in Biopharmaceutical Quality and CMC Regulatory Affairs. He is a past Chair of the Parenteral Drug Association and serves on the San Francisco State University Foundation Board. Mr. Anicetti holds BA and MS degrees in biological sciences from San Francisco State University.
About Coherus BioSciences, Inc.
Coherus is a leading biologics platform company focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medications worldwide. Headquartered in the San Francisco Bay Area and founded by a group of biotech pioneers who helped build America's first generation biotherapeutics industry, Coherus has developed a collaborative business model that leverages a strategic consortium of service providers aligned through ownership and shared incentives. Coherus' global commercialization partnerships include top-tier biopharma companies in Europe, Asia, and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.
Contact – Beth Jimison – email@example.com +1.650.649.3526
SOURCE Coherus Biosciences, Inc.